Efsubaglutide alfa (supaglutide)
GLP-1 · s.c. weekly · Yinnuo (Innogen)
Summary
- Also known as
- Yinnuo / Innogen
- Mechanism
- GLP-1
- Route
- s.c. weekly
- Company
- Yinnuo (Innogen)
- Highest development stage
- approved
- Status (as of data cut)
- Approved in China for T2D (January 2025); obesity phase 2b ENLIGHT positive; obesity phase 3 topline expected end-2026 verify
- Next milestone
- Obesity phase 3
Indications: regulatory and evidence status
| Indication | Code | Status | Evidence |
|---|---|---|---|
| Obesity | 2 phase 3 ongoing | Phase 2b ENLIGHT positive; phase 3 topline expected end-2026 | |
| T2D | 4 approved / in label | NMPA (China), January 2025 | Innogen interim report (HKEX, Aug 2026) |
| CV outcomes | 0 no data | ||
| CKD | 0 no data | ||
| HFpEF | 0 no data | ||
| MASH | 0 no data | ||
| Sleep apnoea | 0 no data | ||
| Knee OA | 0 no data | ||
| Alzheimer's | 0 no data |
4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.
Trial arms: weight, HbA1c and tolerability
| Trial | Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ENLIGHT Phase IIb (NCT06921486) | 20 mg QW | obesity china | 18 | 200 | — | —−10.6 % estimand not specified | — | — | — | — | — | — | — | press release |
| ENLIGHT Phase IIb (NCT06921486) | 20 mg Q2W | obesity china | 18 | 200 | — | —−9.7 % estimand not specified | — | — | — | — | — | — | — | press release |
| SUPER 2 (NCT04998032), phase 2b stage | 1 mg QW | t2d china | 12 | 120 | — | — | −1.1 | — | — | — | — | — | — | press release |
| SUPER 2 (NCT04998032), phase 2b stage | 3 mg QW | t2d china | 12 | 120 | — | — | −1.4 | — | — | — | — | — | — | press release |
| SUPER 2 (NCT04998032), phase 3 stage | 3 mg QW | t2d china | 24 | 171 | — | — | −1.8 vs −0.7 | — | — | 7.6 vs 4.0 | 9.9 vs 1.7 | — | — | press release |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- 3 mg QW: Reported: 1.2 % discontinued for treatment-related adverse events only (not shown on the axis).
Verbatim quotes from the source (7)
- 20 mg QW · weight_unsp · press release
Efsubaglutide α significantly reduced the weight of participants, with reductions of 10.58% and 9.70% in the QW and Q2W groups, respectively.
- 20 mg Q2W · weight_unsp · press release
Efsubaglutide α significantly reduced the weight of participants, with reductions of 10.58% and 9.70% in the QW and Q2W groups, respectively.
- 3 mg QW · hba1c · publication
At week 24 in phase 3, HbA1c decreased by 1.80% with Efsubaglutide 3 mg versus 0.74% with placebo
- 3 mg QW · vomiting · publication
including diarrhoea (21.6% vs. 3.5%), vomiting (9.9% vs. 1.7%), nausea (7.6% vs. 4.0%)
- 3 mg QW · nausea · publication
including diarrhoea (21.6% vs. 3.5%), vomiting (9.9% vs. 1.7%), nausea (7.6% vs. 4.0%)
- 1 mg QW · hba1c · publication
At week 12 in phase 2b, HbA1c decreased by 1.10% with 1 mg and 1.43% with 3 mg
- 3 mg QW · hba1c · publication
At week 12 in phase 2b, HbA1c decreased by 1.10% with 1 mg and 1.43% with 3 mg
Registered trials (4)
From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.
| Trial | Indication | Phase | Status | Start → primary completion | n | Result | Registry |
|---|---|---|---|---|---|---|---|
| NCT06900075 Efficacy and Safety of Efsubaglutide Alfa Injection 3 Mg Q2W in T2D Patients | T2D | Phase 3 | not yet recruiting | 2025-07 → 2026-01 | 88 | not yet recruiting | NCT06900075 |
| ENLIGHT The Efficacy and Safety of Efsubaglutide Alfa Injection in Overweight and Obese Subjects (ENLIGHT) | Obesity | Phase 3 | active not recruiting | 2025-03 → 2026-08 | 1003 | active not recruiting | NCT06921486 |
| SUPER-2 A Study of Efficacy and Safety of Supaglutide in Type 2 Diabetes Patients On Metformin Treatment(SUPER-2) | T2D | Phase 3 | completed | 2021-10 → 2023-06 | 620 | Completed; arm-level results are in the atlas maps (Effect vs cost, Arms) | NCT04998032 |
| SUPER-1 A Study of Efficacy and Safety of Supaglutide in Type 2 Diabetes Patients(SUPER-1) | T2D | Phase 3 | completed | 2021-08 → 2023-06 | 547 | Completed; results not in the atlas yet | NCT04994288 |
Primary sources
- Innogen (Yinnuo). Innogen to present Phase IIb ENLIGHT study results for Efsubaglutide Alfa at ADA 2026 (BioSpace mirror of PR Newswire) [press release]. 2026-05-29. Available from: https://www.biospace.com/press-releases/innogen-to-present-phase-iib-enlight-study-results-for-efsubaglutide-alfa-at-the-2026-ada-scientific-sessions
- Innogen (Yinnuo). Efsubaglutide alfa added to metformin in T2D: randomised, double-blind, placebo-controlled, two-stage adaptive phase 2b/3 trial (SUPER 2). Nat Commun 2026 [publication]. 2026-05-08. Available from: https://www.nature.com/articles/s41467-026-72574-7
How to cite this page
Cite the primary publication for any single result; every value above links to it.